NCT06350812View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 27, 2024

Primary Completion Date

April 29, 2025

Study Completion Date

April 29, 2025

Conditions

Obesity

Interventions

DRUG

PB-119

Administered subcutaneously once a week

DRUG

Placebo

Administered subcutaneously once a week

Trial Locations (1)

410013

The Third XIANGYA Hospital of Central South University, Changsha

All Listed Sponsors

lead

PegBio Co., Ltd.

OTHER

NCT06350812 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects | Biotech Hunter | Biotech Hunter